How to Get Rezdiffra (Resmetirom) in Utah

What Is Rezdiffra and Why Does It Matter for Utah Patients?

Rezdiffra (resmetirom) is the first FDA-approved medication specifically targeting MASH, a progressive liver disease formerly called non-alcoholic steatohepatitis (NASH). The FDA granted accelerated approval in March 2024 based on the MAESTRO-NASH trial, which enrolled 966 patients with biopsy-confirmed MASH and fibrosis stages F1B through F3.

For Utah's estimated 130,000-plus adults living with MASH, according to prevalence modeling from the National Institute of Diabetes and Digestive and Kidney Diseases, this approval opened a pharmacologic option where only lifestyle modification and off-label agents existed before. Resmetirom works by selectively activating the thyroid hormone receptor beta in hepatocytes, which drives hepatic fat oxidation and reduces lipotoxic injury without the cardiac effects seen with non-selective thyroid hormone analogs. At 52 weeks in MAESTRO-NASH, the 100 mg dose achieved MASH resolution without fibrosis worsening in 29.9% of patients versus 9.7% on placebo [1]. Fibrosis improvement by at least one stage occurred in 25.9% of the 100 mg group compared to 14.2% on placebo [1].

Utah patients face a specific access challenge: the state Medicaid program does not cover Rezdiffra for MASH as of mid-2026. Commercial insurance remains the primary payer pathway, and understanding the steps from diagnosis to filled prescription can save weeks of delay.

Step 1: Confirm Your Diagnosis and Fibrosis Stage

Getting Rezdiffra starts with confirming you meet the labeled indication. The FDA-approved prescribing information restricts use to adults with MASH and moderate-to-advanced hepatic fibrosis (stages F2-F3), so your provider needs documented evidence of both steatohepatitis and fibrosis severity.

Two diagnostic pathways satisfy most insurance formularies:

Liver biopsy remains the reference standard. A biopsy showing a NAFLD Activity Score (NAS) of 4 or higher with at least 1 point each in steatosis, lobular inflammation, and hepatocyte ballooning, combined with an Ishak or METAVIR fibrosis stage of F2 or F3, meets both clinical and payer criteria.

Non-invasive testing is increasingly accepted. A FibroScan (vibration-controlled transient elastography) result between 8.0 and 13.9 kPa suggests F2-F3 fibrosis, and an Enhanced Liver Fibrosis (ELF) score above 9.8 adds further confirmation. The American Association for the Study of Liver Diseases (AASLD) 2023 practice guidance endorses combining FibroScan with serum biomarkers such as FIB-4 for staging when biopsy is deferred.

Utah has FibroScan-equipped facilities at University of Utah Health, Intermountain Health locations along the Wasatch Front, and several gastroenterology practices in Salt Lake City, Provo, and St. George. If you are using telehealth, your remote provider can order a FibroScan at a local imaging center and review results electronically.

Step 2: Find a Prescriber in Utah

Any Utah-licensed physician (MD or DO), nurse practitioner, or physician assistant with independent or collaborative prescriptive authority can write a Rezdiffra prescription. No subspecialty certification is required by law, though most prescriptions originate from hepatologists and gastroenterologists familiar with MASH staging and monitoring protocols.

Three practical routes exist for Utah residents:

In-person hepatology. The University of Utah Liver Center and Intermountain Medical Center both have hepatologists experienced with resmetirom. Referral wait times in the Salt Lake area have ranged from 3 to 8 weeks in 2025-2026.

Telehealth. Utah permits synchronous audio-video telehealth prescribing for non-controlled substances under Utah Code 26-60. A provider licensed in Utah, even if physically located elsewhere, can evaluate you via video visit, order labs and imaging at a Utah facility, and electronically prescribe Rezdiffra to a Utah pharmacy. This collapses wait times significantly, especially for patients outside the Wasatch Front corridor.

Primary care with specialist co-management. Some PCPs in Utah will prescribe Rezdiffra after a one-time hepatology consultation confirms the diagnosis, then manage ongoing monitoring themselves. This model works well in rural counties where specialist access is limited.

Step 3: Complete Pre-Prescription Lab Work

Before writing the prescription, your provider will order baseline labs. The FDA label and insurer prior authorization forms typically require the following panel within 90 days of treatment initiation:

• Comprehensive metabolic panel (CMP) including ALT, AST, alkaline phosphatase, total bilirubin, and albumin
• Thyroid function tests (TSH, free T4) to rule out uncontrolled thyroid disease, since resmetirom is a THR-β agonist
• Lipid panel (LDL, HDL, triglycerides, total cholesterol), because resmetirom produces meaningful LDL reductions as a secondary pharmacologic effect
• CBC with differential
• INR/PT if cirrhosis is suspected
• FIB-4 index calculation (age, AST, ALT, platelet count)
• FibroScan or liver biopsy results documenting F2-F3 fibrosis

In the MAESTRO-NASH trial, resmetirom 100 mg reduced LDL cholesterol by approximately 16% at 52 weeks [1], a secondary benefit the American Heart Association has noted may be clinically meaningful for MASH patients with concurrent dyslipidemia.

Your provider should also document your body weight before prescribing, as dosing is weight-based: patients weighing less than 100 kg receive 80 mg daily, while those at or above 100 kg receive 100 mg daily [2].

Step 4: Manage Prior Authorization in Utah

Most commercial insurers in Utah, including SelectHealth (Intermountain's affiliated plan), PEHP (state employee plan), Regence BlueCross BlueShield, and UnitedHealthcare of Utah, require prior authorization for Rezdiffra. The process typically follows this sequence:

1. Provider submits PA request with clinical documentation: confirmed MASH diagnosis, fibrosis stage (biopsy report or FibroScan with FIB-4), baseline labs, BMI, and a statement that lifestyle interventions alone have been insufficient.
2. Insurer clinical review takes 5-15 business days for standard requests. Utah law requires commercial insurers to respond to urgent PA requests within 72 hours.
3. Approval or denial. If denied, your provider can file a peer-to-peer review. The Utah Insurance Department oversees the external review process if internal appeals are exhausted.

Common denial reasons include insufficient documentation of fibrosis stage, missing thyroid function labs, or failure to document prior lifestyle modification attempts. Having a FibroScan report with a numeric kPa value (not just a qualitative reading) and 6-plus months of documented diet and exercise counseling strengthens the submission considerably.

Utah Medicaid (administered through the Utah Department of Health & Human Services) does not list Rezdiffra on its preferred drug list as of May 2026. Medicaid beneficiaries may request an exception through the non-preferred drug authorization process, though approvals remain uncommon without compelling documentation such as liver biopsy showing rapid fibrosis progression.

Step 5: Fill the Prescription at a Utah Pharmacy

Once approved, Rezdiffra can be dispensed through specialty pharmacies or traditional retail pharmacies with access to the drug's distribution network. Madrigal Pharmaceuticals uses a specialty distribution model, meaning not all retail pharmacies stock the medication.

Specialty pharmacy options in Utah include Optum Specialty, Accredo (Express Scripts), and CVS Specialty, all of which ship to Utah addresses and handle the complex billing typical of specialty medications.

503A compounding pharmacies in Utah hold state licenses that permit compounding and dispensing patient-specific prescriptions. While resmetirom itself is a commercially manufactured product and not typically compounded, 503A pharmacies participating in specialty distribution networks can dispense it. Utah's Division of Professional Licensing (DOPL) regulates these pharmacies, and they can ship within the state. If your provider writes an e-prescription, confirm with the receiving pharmacy that they are enrolled in Madrigal's distribution channel before transmission.

The typical timeline from e-prescription to delivery in Utah runs 3-7 business days for specialty pharmacy fulfillment, assuming PA approval is already in place. Patients in rural Utah (Cedar City, Vernal, Logan) should expect the upper end of that range due to shipping logistics.

Cost and Financial Assistance

Rezdiffra carries a list price of approximately $47,400 per year. Out-of-pocket costs vary dramatically by plan structure.

Madrigal Pharmaceuticals offers the Rezdiffra copay assistance program for commercially insured patients, which can reduce copays to as little as $0 per month for eligible individuals. Patients without commercial insurance or those on government programs (Medicare, Medicaid, Tricare) do not qualify for copay cards but may apply to Madrigal's patient assistance program for potential free drug access.

The MAESTRO-NASH trial data published in the New England Journal of Medicine has supported some insurers in building coverage policies, since the trial demonstrated statistically significant histologic improvement, a measurable clinical endpoint that payers can tie to long-term cost avoidance from reduced cirrhosis progression and liver transplant need.

A 2024 cost-effectiveness analysis published in Hepatology estimated that resmetirom could be cost-effective at a willingness-to-pay threshold of $100,000 per quality-adjusted life year if treatment prevents progression to decompensated cirrhosis in even a modest fraction of patients [3].

Monitoring and Follow-Up After Starting Rezdiffra

Once you begin resmetirom, your Utah provider should schedule follow-up labs at 12 weeks and then every 3-6 months. Key monitoring parameters include:

• Liver enzymes (ALT, AST): The FDA label warns about potential hepatotoxicity. ALT elevations above 5 times the upper limit of normal require treatment discontinuation [2].
• Thyroid function (TSH): While resmetirom is selective for THR-β, periodic thyroid monitoring ensures no clinically significant TSH suppression occurs.
• Lipid panel: Track the LDL-lowering effect, which may allow dose reduction or discontinuation of concurrent statin therapy in some patients.
• Repeat FibroScan: At 12-18 months, a follow-up FibroScan can assess whether liver stiffness has improved, an outcome seen in MAESTRO-NASH where fibrosis improvement occurred in 25.9% of the 100 mg group at one year [1].

Dr. Stephen Harrison, principal investigator of MAESTRO-NASH, noted in his 2024 NEJM publication: "Resmetirom is the first therapy to demonstrate both resolution of NASH and improvement in fibrosis in a phase 3 trial, representing a meaningful advance for patients with this progressive disease" [1].

The AASLD 2024 guidance update recommends that patients on resmetirom undergo hepatic imaging reassessment no later than 18 months after treatment initiation. If no histologic or imaging improvement is evident, the treating provider should re-evaluate continued therapy.

Telehealth-Specific Considerations for Utah

Utah's telehealth framework is among the more permissive in the western United States. The state does not require an in-person visit before a telehealth prescriber can write a prescription for a non-controlled substance like resmetirom. Synchronous video visits satisfy the provider-patient relationship requirement under Utah Administrative Code R156-1-602.

For patients in Utah's rural counties (San Juan, Garfield, Wayne, Daggett), telehealth may be the only practical pathway. A board-certified hepatologist or gastroenterologist licensed in Utah can conduct the evaluation remotely, order labs and FibroScan at the nearest available facility, review results asynchronously, and transmit the prescription electronically to a specialty pharmacy that ships statewide.

One logistical consideration: FibroScan availability drops sharply outside the Wasatch Front. Patients in southeastern Utah may need to travel to St. George or Provo for the scan itself, even if the rest of the care process is telehealth-based. Some providers accept MRI-PDFF (proton density fat fraction) as an alternative imaging measure when FibroScan is inaccessible, though insurer acceptance of MRI-PDFF for PA purposes varies by plan.

How Rezdiffra Compares to Other MASH Treatments Available in Utah

Resmetirom is currently the only FDA-approved MASH-specific therapy. Other medications sometimes used off-label for MASH in Utah include:

• Pioglitazone (Actos): A thiazolidinedione with evidence from the PIVENS trial (NEJM 2010) showing NASH resolution in 47% of patients versus 21% on placebo, but associated with weight gain (mean 4.7 kg) and bone density loss [4].
• Vitamin E (800 IU/day): Also studied in PIVENS, with 36% achieving NASH resolution. The AASLD limits its recommendation to non-diabetic adults due to concerns about increased all-cause mortality at high doses raised by a meta-analysis in Annals of Internal Medicine [5].
• GLP-1 receptor agonists (semaglutide, liraglutide): The phase 2 semaglutide NASH trial (NEJM 2021) showed NASH resolution in 59% of patients on 0.4 mg daily, though fibrosis improvement did not reach statistical significance [6]. These agents address co-occurring obesity and type 2 diabetes but lack a MASH-specific FDA indication.

Resmetirom's mechanism (THR-β agonism) is distinct from all of these, and combination strategies pairing resmetirom with a GLP-1 agonist are under active investigation. For Utah patients already on semaglutide or tirzepatide for weight management, adding resmetirom targets a complementary hepatic pathway.